NCT04504513Approved For Marketing不适用
Expanded Access Program: Trilaciclib for Chemotherapy-induced Myelosuppression in Patients Receiving Chemotherapy for Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
The purpose of this expanded access protocol is to provide access to trilaciclib for chemotherapy-induced myelosuppression in patients receiving chemotherapy as a treatment for small cell lung cancer (SCLC).
Patients will receive trilaciclib intravenously as a 30-minute infusion prior to chemotherapy dosing and on each day that chemotherapy is administered.
Supplementary to providing access to trilaciclib, this expanded access program will also capture Real World Data to help inform subsequent trilaciclib development.
Requests for access to trilaciclib will be managed by Bionical Emas. G1 Therapeutics will review eligibility of, as well as complete a medical review of, each patient access request.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who require treatment with either intravenous etoposide + platinum (carboplatin or cisplatin) ± an anti-PDL1 or anti-PD1 checkpoint inhibitor OR intravenous topotecan
- •Pathologically confirmed diagnosis of SCLC
- •Extensive-stage or limited-stage SCLC; patients with limited-stage SCLC receiving chemotherapy with concurrent radiation are NOT eligible.
- •Age ≥ 18 years
- •ECOG 0 to 2
- •Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L at time of initiation of therapy in this EAP
- •Platelet count ≥ 100 x 10^9/L at time of initiation of therapy in this EAP
- •Glomerular filtration rate (GFR) of ≥ 20 mL/minute at time of initiation of therapy in this EAP
- •Total bilirubin ≤ 1.5x ULN (upper limit normal) at time of initiation of therapy in this EAP
- •AST or ALT ≤ 2.5x ULN (≤ 5x ULN in the presence of liver metastases) at time of initiation of therapy in this EAP
- •QTcF interval ≤ 450 msec (males) or ≤ 470 msec (females) at screening (confirmed on repeat). For patients with ventricular pacemakers, QTcF ≤ 500 msec
- •No personal or family history of long QT syndrome
- •Female patient is not lactating or currently pregnant, or plans to become pregnant, while participating in this expanded access program
- •Female patients of reproductive potential agree to use effective contraception while in the program and for at least 3 weeks after the last dose of trilaciclib
- •Patient agrees not to participate in another expanded access program or clinical trial with an experimental treatment during participation in this EAP
- •Active clinical trial with trilaciclib is not available (or if available, it is not appropriate) for the patient
排除标准
- •Patients requiring treatment with oral etoposide or oral topotecan
- •Patients outside of the United States
研究者
相似试验
Available
不适用
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 DeficiencyMonocarboxylate Transporter 8 DeficiencyAllan-Herndon-Dudley SyndromeNCT05911399Rare Thyroid Therapeutics International AB
Approved For Marketing
不适用
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma PatientsRelapsed or Refractory Multiple MyelomaNCT05463939Janssen Research & Development, LLC
No Longer Available
不适用
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and GliomasGlioma of BrainGlioblastomaNCT03460782Center Trials & Treatment
No Longer Available
不适用
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple SclerosisNCT02807285Genentech, Inc.
No Longer Available
不适用
Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's DiseaseLate Onset Alzheimer DiseaseNCT03624842Cyclo Therapeutics, Inc.